EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. - Wikidata - awgldk - TriplyDB

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

http://www.wikidata.org/entity/Q36687288

about

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice Osimertinib making a breakthrough in lung cancer targeted therapy Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR.Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer Drug Resistance to EGFR Inhibitors in Lung Cancer Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.Resisting Resistance: Targeted Therapies in Lung Cancer.Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer.Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles.Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR.Resistance to Therapy.Targeted Covalent Inhibitors for Drug Design.Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors.Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets.Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy.Structural basis of mutant-selectivity and drug-resistance related to CO-1686.Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR.

P2860

Q26741998-3BE4D3F4-D0D1-47C8-A09D-9E8488656C57 Q28069708-E32FE50C-E00C-48C9-B247-9F5A14EEDFE2 Q28075511-A851D674-4841-4EFD-B028-2C2153942F83 Q28075704-A7E91325-0258-40E9-BEAD-4ECAA91A22CF Q28075800-F2818CA1-758E-425D-80C8-53349701BB9D Q28079689-250541A5-181D-4493-A116-3B1D8A4BDE6E Q33740707-29893F3A-9254-43C1-BB84-DEBEE4D07324 Q34484794-FDA92550-0056-4D94-83ED-EE3F85A62EC9 Q34497467-8D70C0D2-DF9A-46D3-A368-62100C134B61 Q34550460-B54A8F15-3237-4F39-B055-10A2E7FC2B87 Q35962944-8A2E9851-C69E-4FA6-8A7C-800C78DD1D9F Q36149008-D175888B-6D48-4718-8C53-811953C06F07 Q36427381-42E328DE-B90C-496D-B182-83AA18AB2EDB Q36801144-6D494FCE-D35C-4E1F-91BE-6AA9D1F4C033 Q36834883-3ACB80DE-77DE-4AB4-88E1-70110D27D037 Q37000646-CFE5AD76-CC0B-438E-8212-1532E38F45E4 Q37057914-DA98DA35-55F8-4F13-87D3-840852486127 Q37085219-CE549D2E-358B-4492-8050-A800C634EF8B Q37388238-964FDF6A-DBDF-46FA-811C-1B128D2F1499 Q37687088-EB19BD9E-C8A3-471C-9FE8-8B4692E57C78 Q38598893-649D8B7B-E107-40E8-989E-4C4014477BCF Q38729111-30D87AD4-94A3-4112-A64D-F45C8CABD42F Q38731759-E2E102C0-C9CC-4546-999B-1BC22904201E Q38756349-75CE62BC-0D56-4A06-AF73-A07784F3952D Q38766833-666494A1-BE28-446D-98FC-03997CBC71EC Q38766913-82199340-27A8-4C1A-A0DD-B9A37349E061 Q38790929-67E727D7-5EB6-447D-A4AD-A44923CFE105 Q38821038-8FA5DD0F-367A-441E-A36F-44D11B7BF606 Q38838227-6272D826-4619-4B96-B810-5A7C80630A8C Q38930367-AC4B7F7F-0F96-4897-ABB1-30C07B50D6DB Q38931379-350FDC07-7EFF-45A8-84B3-05EE5F0D0C38 Q38988061-F5E3EA1F-9F8E-431C-A12E-9D3278614903 Q38991958-528AFE73-0DDE-4FEF-A0A4-2788AF65CE92 Q39079553-7816628A-2116-4B43-8F62-CBF586E74195 Q39114552-79E60703-17D4-4B04-82F9-CC85E7C65ED1 Q39172297-458EC8F6-75ED-4AAD-8381-93288C01D188 Q39255218-C6B252A0-B04C-481C-A082-1FDCD317DD28 Q41593246-A6A45E4F-1AE4-489A-94BB-C29B253043E7 Q41911703-EDCC9B73-6A54-4C26-932B-689ECA84273C Q42096010-DC3B0181-D643-4914-8BEB-B03CD811324B

P2860

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

http://www.wikidata.org/entity/Q36687288

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

@ast

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

@en

type

label

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

@ast

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

@en

prefLabel

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

@ast

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

@en

P1433

Q36687288-A769090A-719B-4510-9E92-529CE44AEE2D

P1476

Q36687288-640CC2AE-CDEA-4707-9A19-C0B8B0E546BD

P2093

Q36687288-271A39D0-6D57-47A9-B55C-FE50DE974261

Q36687288-578AED11-6F3A-4973-A2EC-C5778C360C40

Q36687288-5BB1B957-5219-4E9E-9A4D-62032C02E20A

Q36687288-B2F2097C-8279-4A23-B2A0-86BF9D59D8A4

Q36687288-E2B823F5-93B0-4B54-8DFC-063EB83BDF03

Q36687288-F407EB61-8EC0-437E-8D2A-58AFCCF5A4BA

Q36687288-FDD47FA7-BB76-41BC-BFD8-0BF292C2B245

P2860

Q36687288-0B1774DC-F99D-4678-9576-0485F7337F94

Q36687288-0D5DB531-5E5B-4636-B048-CEBF5A5ED8AA

Q36687288-16B39A7A-0A08-480F-A24A-DDE68F9C62E1

Q36687288-18BB5154-4910-4D0D-9EE4-416D638E40C3

Q36687288-25DEC7DB-1783-43AC-BF7A-BB986DD64B96

Q36687288-28109D5F-9D9F-4393-9D71-DAA2FCEFD01C

Q36687288-29AAF7B3-D5BD-4251-B132-3E2E06EDD9B3

Q36687288-2B367B17-04C6-4DC3-A86B-2EF37D882492

Q36687288-385F6D37-8DD0-4888-9950-2FD1FE93AF37

Q36687288-3B6574E0-8F28-49F2-A88A-EE9696B0C686

P304

Q36687288-F1501183-BE2C-4412-8833-600FC6F2D23D

P31

Q36687288-AA98F084-D064-46FD-AFD3-CE5742705760

P356

Q36687288-8CC841F3-717C-486E-B01C-F57B10188218

P407

Q36687288-85852B47-3B14-4F13-8256-FE2CC8C71B30

P433

Q36687288-8543AAC3-59F9-4819-A627-7216F3C9D5D7

P478

Q36687288-1D8B20DA-1B5C-40BF-A808-4A486A5AE463

P50

Q36687288-AA174B2C-C5D5-431F-9957-0F5AF81A0DE0

P577

Q36687288-2A702141-71F9-4AB2-AF94-C5FA8A5CFFBB

P698

Q36687288-969DFED1-EAC1-4F03-B610-E54A1846C078

P932

Q36687288-A0A7AB1D-B949-4084-9BA6-84C3BEDCCB67

P356

1078-0432.CCR-14-2789

P1433

Clinical Cancer Research

P1476

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

@en

P2093

Cai-Hong Yun

http://www.w3.org/2001/XMLSchema#string

Dalia Ercan

http://www.w3.org/2001/XMLSchema#string

Hwan Geun Choi

http://www.w3.org/2001/XMLSchema#string

Marzia Capelletti

http://www.w3.org/2001/XMLSchema#string

Michael J Eck

http://www.w3.org/2001/XMLSchema#string

Nathanael S Gray

http://www.w3.org/2001/XMLSchema#string

Ting Xie

http://www.w3.org/2001/XMLSchema#string

P2860

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

P304

3913-3923

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-2789

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25948633

http://www.w3.org/2001/XMLSchema#string

P932

4791951

http://www.w3.org/2001/XMLSchema#string